Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 1.68 is in line with its 5-year average of 1.73, near the high end of its 5-year range (0.00–1.97).
As of the fiscal period ended Tuesday, June 30, 2026. 3.95% below its 12-month average of 1.75.
Reported quarterly quick ratio; no daily interpolation. Q3 FY2026 (2026-06-30): 1.68.
QUICK RATIO (ACID-TEST)
1.68
QUICK RATIO (ACID-TEST) AVG TTM
1.75
QUICK RATIO (ACID-TEST) AVG 3Y
1.71
QUICK RATIO (ACID-TEST) AVG 5Y
1.73
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
-3.95%
CURRENT VS 3Y AVG
-1.88%
CURRENT VS 5Y AVG
-3.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.19
median of 771 covered companies
CURRENT VS SECTOR MEDIAN
-47.35%
vs the sector median at left
Embecta Corp.
Market Cap
$359.96M
Quick Ratio (Acid-Test)
1.68
TTM Avg
1.75
3Y Avg
1.71
5Y Avg
1.73
Market Cap
$358.19M
Quick Ratio (Acid-Test)
3.76
TTM Avg
4.71
3Y Avg
6.65
5Y Avg
8.92
Market Cap
$354.76M
Quick Ratio (Acid-Test)
5.66
TTM Avg
6.21
3Y Avg
5.34
5Y Avg
8.05
Market Cap
$354.14M
Quick Ratio (Acid-Test)
24.16
TTM Avg
12.00
3Y Avg
8.65
5Y Avg
7.93
Market Cap
$363.70M
Quick Ratio (Acid-Test)
12.19
TTM Avg
4.83
3Y Avg
10.20
5Y Avg
8.85
Market Cap
$352.43M
Quick Ratio (Acid-Test)
29.52
TTM Avg
9.54
3Y Avg
9.83
5Y Avg
10.59
Market Cap
$351.50M
Quick Ratio (Acid-Test)
8.24
TTM Avg
5.34
3Y Avg
5.79
5Y Avg
4.44
Market Cap
$374.20M
Quick Ratio (Acid-Test)
2.39
TTM Avg
2.24
3Y Avg
1.74
5Y Avg
3.80
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Embecta Corp. (EMBC) | $359.96M | 1.68 | 1.75 | 1.71 | 1.73 |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $358.19M | 3.76 | 4.71 | 6.65 | 8.92 |
| Ocugen, Inc. (OCGN)vs › | $357.76M | 0.80 | 1.96 | 2.47 | 5.28 |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $354.76M | 5.66 | 6.21 | 5.34 | 8.05 |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $354.14M | 24.16 | 12.00 | 8.65 | 7.93 |
| Opus Genetics, Inc. (IRD)vs › | $363.70M | 12.19 | 4.83 | 10.20 | 8.85 |
| Relmada Therapeutics, Inc. (RLMD)vs › | $352.43M | 29.52 | 9.54 | 9.83 | 10.59 |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $351.50M | 8.24 | 5.34 | 5.79 | 4.44 |
| Canopy Growth Corporation (CGC)vs › | $374.20M | 2.39 | 2.24 | 1.74 | 3.80 |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $379.73M | 5.88 | 5.65 | 4.80 | 5.41 |
Quick Ratio
1.68
Excludes inventory
Current Ratio
1.68
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 1.68 |
| 2026-03-31 | 1.68 |
| 2025-12-31 | 1.87 |
| 2025-09-30 | 1.73 |
| 2025-06-30 | 1.78 |
| 2025-03-31 | 1.83 |
| 2024-12-31 | 1.67 |
| 2024-09-30 | 1.58 |
| 2024-06-30 | 1.61 |
| 2024-03-31 | 1.79 |
| 2023-12-31 | 1.75 |
| 2023-09-30 | 1.69 |
| 2023-06-30 | 1.60 |
| 2023-03-31 | 1.67 |
| 2022-12-31 | 1.67 |
| 2022-09-30 | 1.80 |
| 2022-06-30 | 1.97 |
| 2022-03-31 | 1.80 |
| 2021-12-31 | 0.87 |
| 2021-09-30 | 1.06 |
| 2021-06-30 | 0.00 |
| 2021-03-31 | 0.00 |
| 2020-12-31 | 0.00 |
